Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy.